Kura Oncology announced that its investigational drug, ziftomenib, has been granted Breakthrough Therapy Designation, BTD, by the U.S. Food and Drug Administration, FDA, for the treatment of patients with relapsed/refractory NPM1-mutant acute myeloid leukemia. FDA granted BTD for ziftomenib based on data from Kura‘s ongoing KOMET-001 clinical trial in patients with R/R NPM1-mutant AML. BTD is for a drug that treats a serious or life-threatening condition and for which preliminary clinical evidence indicates the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over available therapies. “We are highly encouraged by FDA’s decision to grant Breakthrough Therapy Designation to ziftomenib, recognizing its potential as an innovative medicine for patients with relapsed/refractory NPM1-mutant AML,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. “NPM1-mutant AML represents approximately 30% of new AML cases annually, and this designation reflects that NPM1-mutant AML is a disease of significant unmet need for which there is no approved targeted therapy as well as the fact that ziftomenib offers potential to demonstrate substantial improvement over available therapies. We remain committed to bringing ziftomenib to the market as quickly as possible and look forward to working more closely with FDA to bring our ziftomenib program to patients in urgent need of effective treatments.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
- Kura Oncology to Participate in Stifel Targeted Oncology Forum
- Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Kura Oncology reports inducement grants under Nasdaq listing rule
- Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma